Office for Technology Commercialization

Quantitative Schizophrenia Diagnostic

Technology #20130002

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Schizophrenia DetectionSchizophrenia DiagnosticSchizophrenia
Robert F. Miller
Professor, Department of Neuroscience
External Link (
Managed By
Kevin Nickels
Technology Licensing Officer 612-625-7289
Patent Protection

US Patent Pending 20150105689

Quantitative Schizophrenia Evaluation

A method has been developed that quantitatively evaluates neurological conditions, such as schizophrenia. Hypofunction of N-methyl-D-Aspartate (NMDA) receptors in the brain have been demonstrated to be correlated with the presence of schizophrenia. Moreover, dysfunction in the central nervous system should be mirrored in the retinal synaptic systems. Visually evoked responses have produced unique retinal signatures of NMDA receptor activation that can serve as a biomarker or classifier of schizophrenia. Specific metrics based on the unique signatures recorded using pattern electroretinography (pERG) have been demonstrated to classify patients into schizophrenia and control groups with high statistical significance.

MN-IP Try and Buy
  • $5000 for a twelve month trial
  • Up to 18 month trial period
  • Trial fee is waived for MN companies or if sponsoring $50,000+ research with the University
  • No US patent costs during trial
  • $10,000 conversion fee (TRY to BUY)
  • Royalty rate of 3% (2% for MN company)
  • Royalty free for first $1M in sales

** View the Term Sheet **
** Contact Kevin Nickels for specific details. **

Applications for Schizophrenia Biomarker

Schizophrenia affects approximately 1% of the global population. The capability to make early diagnosis before the disease manifests itself, provides the opportunity to head off non-reversible brain damage. Currently schizophrenia treatments are directed at treatment of symptom suppression after irreversible damage has occurred. With a new quantitative diagnostic tool and biomarker, early intervention and improved clinical outcome may be possible.


  • Quantitative diagnostic of schizophrenia presence
  • Potential to identify dysfunction prior to the occurrence of symptoms and irreversible brain damage
  • Leverages capabilities of electroretinography (ERG) services, which are used clinically

Phase of Development Human studies of 23 schizophrenia subjects and 23 health controls with a p-value of 0.01